ÂÜÀòÂÒÂ×

Lawrence Fong, M.D. is Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at the UCSF. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity Program in the Helen Diller Family Comprehensive Cancer Center. He is a physician-scientist in the Department of Medicine, Division of Hematology/Oncology directing both a translational research program and an NIH funded research lab. He has focused on cancer immunotherapy for over 20 years and has been involved in both pre-clinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors. Dr. Fong's research focuses on understanding the ways by which immunotherapies can lead clinical responses and well as treatment-induced side effects. This work includes tracking antigen-specific T cell responses in both pre-clinical models as well as treated cancer patients as well as developing biomarkers that are associated with clinical outcomes. The Cancer Immunotherapy Program that he directs performs early phase and complex clinical trials across different disease indications. This program also includes a translational laboratory that performs mechanistic studies on samples derived from patients undergoing treatment.